Table 4 Multivariate analysis . LS . FN... | American Society of Hematology

Table 4

Multivariate analysis

	LS		FN
	β-coefficient	P	β-coefficient	P
All patients
Sex	−0.01	.91	0.18	.03
Initial diagnosis	0.05	.78	0.14	.40
Age at diagnosis	0.06	.57	−0.005	.96
Follow-up	0.04	.69	0.06	.56
Corticotherapy	0.19	.23	0.14	.35
HSCT	0.05	.56	−0.24	.006
Chemotherapy group
Sex	−0.11	.3	0.12	.26
Initial diagnosis	−0.06	.58	−0.04	.67
Age at diagnosis	−0.09	.52	−0.18	.19
Follow-up	0.01	.94	0.01	.94
CNS radiation	0.001	.99	−0.06	.62
HSCT group
Sex	0.13	.39	0.15	.31
Age at HSCT	0.38	.03	0.3	.07
Follow-up	0.11	.50	0.14	.39
TBI	0.23	.12	0.14	.31
Significant GVHD*	−0.11	.41	−0.15	.25
Hypogonadism	−0.17	.30	−0.32	.04

	LS		FN
	β-coefficient	P	β-coefficient	P
All patients
Sex	−0.01	.91	0.18	.03
Initial diagnosis	0.05	.78	0.14	.40
Age at diagnosis	0.06	.57	−0.005	.96
Follow-up	0.04	.69	0.06	.56
Corticotherapy	0.19	.23	0.14	.35
HSCT	0.05	.56	−0.24	.006
Chemotherapy group
Sex	−0.11	.3	0.12	.26
Initial diagnosis	−0.06	.58	−0.04	.67
Age at diagnosis	−0.09	.52	−0.18	.19
Follow-up	0.01	.94	0.01	.94
CNS radiation	0.001	.99	−0.06	.62
HSCT group
Sex	0.13	.39	0.15	.31
Age at HSCT	0.38	.03	0.3	.07
Follow-up	0.11	.50	0.14	.39
TBI	0.23	.12	0.14	.31
Significant GVHD*	−0.11	.41	−0.15	.25
Hypogonadism	−0.17	.30	−0.32	.04

Significant GVHD indicates acute GVHD grades II, III, or IV or chronic extensive GVHD.